About Us

`We are a small clinical-stage drug development company with a focus on developing therapeutics for Duchenne muscular dystrophy. We run under a venture philanthropy model, through collaborations and partnerships with non-profit foundations and government agencies in both the US and the EU. As such, we keep the focus on stake holders rather than stock holders.

Our lead compound, vamorolone, is a steroidal-type anti-inflammatory that has multiple additional properties chemically tuned for DMD. These value added features include epleronone-like properties to improve heart function, and membrane stabilization properties to counteract dystrophin deficiency.

ReveraGen’s confict of interest policy can be found here.